Deutsche Bank announced on Friday that it had raised its target price for Euroapi shares from five to six euros, stating that it expects the pharmaceutical company's forthcoming publication to provide greater clarity on its short- and medium-term prospects.

The research firm - which is maintaining its 'keep' recommendation on the stock - says it expects the group to unveil, on February 28, organic growth of 5% for its second fiscal half, accompanied by an adjusted Ebitda margin of 8%.

The analyst warns, however, that investors' attention will be focused primarily on the conclusions of the strategic review, forecasts for 2024 and the progress of the recruitment process for a new CEO, all of which he believes should provide greater visibility as to the direction the company is likely to take.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.